Oncovita, winner of the « Innovations in biotherapies and biomanufacturing » call for projects, will benefit from €4.5 million in funding under the France 2030 investment plan, and has completed a €3.5 million round of financing from private investors to support the development of its MVdeltaC immunotherapeutic vaccine in oncology. Voir la version française
October 16, 2023 Background: Oncovita, a biotech company spin-off from Institut Pasteur, Paris, is developing a therapeutic vaccine in oncology based on Measovir®, a proprietary technology derived from the safe and highly immunogenic measles attenuated vaccine virus (MV). MV is a paramyxovirus with a negative strand RNA genome. The MV specific tropism for cancer
October, 2023 Abstract The measles vaccine (MV) delivery platform has undergone development from preclinical to clinical stages, demonstrating its ability to adapt rapidly and effectively to different pathogens. The live pediatric MV holds extensive history of safety and efficacy, along with its established large-scale manufacturing capacity. To further